Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules
Executive Summary
Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein
You may also be interested in...
Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology
Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy